| Mrs Stephanie M Davis, SLP | |
|
70 N Broadway St, Akron, OH 44308-1911 | |
| (330) 338-5498 | |
| Not Available |
| Full Name | Mrs Stephanie M Davis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 70 N Broadway St, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972900314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Stephanie M Davis, SLP 962 Hereford Dr, Akron, OH 44303-1204 Ph: (330) 338-5498 | Mrs Stephanie M Davis, SLP 70 N Broadway St, Akron, OH 44308-1911 Ph: (330) 338-5498 |
News Archive
A study published in the September 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that young adults with an autism spectrum disorder have more difficulty transitioning into employment than their peers with different disabilities.
High blood pressure is a major risk factor for heart attack, stroke, and renal failure, but one out of four people don't even know they have it.
Neuroscientists have long held that the brains of children thin down over time. However, this was on the basis of older imaging techniques. Now, using cutting-edge technology in the form of quantitative magnetic resonance imaging (qMRI), a team of researchers has found that the apparent thinning is due in part to myelin formation around the cortical nerve fibers. These very interesting findings, published in the journal PNAS on September 23, 2019, will drive further research on the link between cortical function and structure.
AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.
Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
› Verified 5 days ago
Michele Y Gunther, S.P.L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Jamie Blaylock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 450 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-376-0153 | |
Kimberly Marie Gibbons, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2425 Foxboro Ave, Akron, OH 44305 Phone: 330-631-5678 | |
Kristin Weaver, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Mrs. Elizabeth Kinzig, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Wyant Rd, Akron, OH 44313 Phone: 330-836-7953 | |
Mrs. Andrea P. Brewer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 181 Polsky Building, Akron, OH 44325 Phone: 330-972-8189 Fax: 330-972-7884 | |
Mary Mariani-walker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-873-3396 |